Iron Absorption Physiology and Deficiency
Iron deficiency (serum ferritin <30 ng/mL; affects 2 billion globally; most prevalent nutritional deficiency; disproportionate in menstruating women, vegetarians/vegans, athletes, and infants) impairs haemoglobin synthesis (haem iron in erythrocytes: 70% body iron), myoglobin O2 storage in muscle, cytochrome c oxidase (Complex IV) OXPHOS, ribonucleotide reductase (DNA synthesis), and ferroptosis resistance (GPx4 requires selenium + GSH + iron-independent peroxidase; but lipid peroxide accumulation in iron excess drives GPx4-dependent ferroptosis). Iron absorption: haem iron (Fe2+; dietary haem from myoglobin/haemoglobin; absorbed via HCP1; 20–30% bioavailability; competitive advantage) and non-haem iron (Fe3+ inorganic; reduced to Fe2+ by duodenal cytochrome b/DCYTB + ascorbate at brush border; transported by DMT1/SLC11A2 → enterocyte iron pool → ferroportin/SLC40A1 + ceruloplasmin ferroxidase Fe2+→Fe3+ → transferrin binding → circulation). Non-haem bioavailability: 5–20% (strongly inhibited by phytate, polyphenols, calcium, fibre; enhanced by ascorbate, citric acid, fermented foods).
Spirulina Mechanisms in Iron Bioavailability
Phytochelated Iron: Organic Acid Complexation
Spirulina iron (28–35 mg/100g; predominantly non-haem) exists in several forms: (1) phycocyanin-chelated iron (coordinated to phycocyanobilin nitrogen atoms and cysteine sulphur ligands of phycocyanin α/β subunits; Fe2+/Fe3+ with log K 8–12; released during gastric proteolysis to low-affinity organic acid complexes); (2) iron-organic acid salts (ferrous malate, ferrous citrate, ferrous glutamate; log K 3–5; soluble at pH 6–7 in proximal small intestine; compete with inhibitory phytate Fe complexes log K 8–12); (3) ferritin-bound iron (~5–10% total). Organic acid complexes maintain iron solubility in the alkaline duodenal environment (pH 5.5–7.5) where inorganic iron hydroxide Fe(OH)3 precipitates (log Ksp ~39), maintaining bioavailable Fe2+ pool for DMT1 transport. Estimated bioavailability: 15–25% (comparable to ferrous sulphate; superior to ferric oxide).
Ascorbate-Driven Fe3+→Fe2+ Reduction and DMT1 Transport
DMT1 (divalent metal transporter 1; SLC11A2; apical enterocyte brush border; H+-coupled; transports Fe2+, Zn2+, Mn2+, Cu2+, Cd2+) exclusively accepts Fe2+; dietary Fe3+ must be reduced by duodenal cytochrome b (DCYTB; requires ascorbate as electron donor) or ascorbate directly in the intestinal lumen before DMT1 transport. Spirulina ascorbate content (limited; ~10–15 mg/100g) supplemented by dietary vitamin C co-consumption provides the reducing environment for Fe3+→Fe2+ conversion at the brush border. MDA (malondialdehyde) from food processing can oxidise Fe2+ back to Fe3+; spirulina antioxidant phycocyanin reduces lumenal ROS, protecting Fe2+ from re-oxidation between DCYTB reduction and DMT1 transport. DMT1 expression is upregulated by iron deficiency via IRE/IRP (iron-responsive element/iron regulatory protein) pathway; spirulina supports this homeostatic regulation without causing DMT1 downregulation seen with large-dose iron supplements.
Ceruloplasmin Copper Co-Provision and Ferroportin Export
Basolateral iron export from enterocytes requires ferroportin (SLC40A1; the sole cellular iron exporter; regulated by hepcidin-driven ubiquitination) coupled to ceruloplasmin (GPI-anchored form on enterocytes; soluble form in plasma) ferroxidase activity (Fe2+ → Fe3+; Fe3+ loads onto apo-transferrin). Without ferroxidase activity, Fe2+ accumulates inside enterocytes and is not released to circulation. Spirulina copper provision (0.5–0.8 mg/100g; 30–40% bioavailable; phytochelated) supports hepatic ceruloplasmin synthesis and enterocyte hephaestin (GPI-ceruloplasmin homologue; brush border) copper loading. Adequate copper maintains ferroportin-mediated iron export efficiency; copper deficiency causes paradoxical iron retention in enterocytes and anaemia despite adequate iron intake.
Hepcidin Modulation and Inflammatory Iron Restriction
Hepcidin (HAMP; liver-derived; 25-amino acid peptide; master iron regulator; binds ferroportin → internalisation → lysosomal degradation) is upregulated by: iron loading (BMP6/SMAD signalling via BMPR2/HJV), inflammation (IL-6 → STAT3 → hepcidin gene transcription), and hypoxia-independent HIF-2α signals. In inflammatory/chronic disease anaemia, hepcidin-driven ferroportin degradation traps iron in macrophages/hepatocytes/enterocytes, reducing circulating transferrin-bound iron for erythropoiesis. Spirulina IL-6 suppression (−25–40%) reduces STAT3-driven hepcidin transcription (−15–25% hepcidin in inflammatory models), partially relieving the inflammatory iron lock-down and improving functional iron availability for erythropoiesis. Haemoglobin +0.3–0.6 g/dL in iron-deficient anaemia at 12 weeks.
Clinical Outcomes in Iron Status
- Serum ferritin (iron-deficient): +8–18 ng/mL at 12 weeks (5–10g daily)
- Haemoglobin (mild anaemia): +0.3–0.6 g/dL at 12 weeks
- Transferrin saturation: +3–8% points
- Hepcidin (inflammatory anaemia): −15–25%
- Serum CRP (inflammation reducing iron): −20–35%
- Physical performance (iron-deficient TE/anaemia): +10–20%
Dosing and Drug Interactions
Iron deficiency (non-anaemic): 5–10g daily with vitamin C-rich food; 12–24 weeks to replete ferritin. Iron deficiency anaemia: Spirulina as adjunct to ferrous sulphate; not sufficient as sole therapy for moderate/severe IDA. Iron supplements (ferrous sulphate): Take 2h apart to avoid DMT1 competition; spirulina phycocyanin antioxidant reduces GI oxidative stress from iron supplementation. Calcium: Separate calcium supplements by 2h; calcium competes with DMT1 transport. Tea/coffee: Polyphenol inhibition; take spirulina 1h before or 2h after high-tannin beverages. Summary: Iron 15–25% bioavailable, ferritin +8–18 ng/mL, Hb +0.3–0.6 g/dL, hepcidin −15–25%; dosing 5–10g with vitamin C for 12–24 weeks. NK concern: low.